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The main function attributed to the Rev proteins of immunodeficiency viruses is the shuttling of viral RNAs containing
the Rev responsive element (RRE) via the CRM-1 export pathway from the nucleus to the cytoplasm. This restricts
expression of structural proteins to the late phase of the lentiviral replication cycle. Using Rev-independent gag-pol
expression plasmids of HIV-1 and simian immunodeficiency virus and lentiviral vector constructs, we have observed
that HIV-1 and simian immunodeficiency virus Rev enhanced RNA encapsidation 20- to 70-fold, correlating well with
the effect of Rev on vector titers. In contrast, cytoplasmic vector RNA levels were only marginally affected by Rev.
Binding of Rev to the RRE or to a heterologous RNA element was required for Rev-mediated enhancement of RNA
encapsidation. In addition to specific interactions of nucleocapsid with the packaging signal at the 59 end of the
genome, the Rev/RRE system provides a second mechanism contributing to preferential encapsidation of genomic
lentiviral RNA.
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Introduction
Virus particles of HIV-1, the major cause of the AIDS
epidemic, and other members of the lentivirus family of
retroviruses contain an RNA genome. After viral entry, the
genomic RNA is reverse transcribed into DNA and integrates
into the genome of the host cell. The integrated proviral DNA
is transcribed by RNA polymerase II. Complex alternative
splicing events with a major splice donor in the 59
untranslated region (UTR) generate viral mRNAs encoding
Env and a number of small regulatory proteins. The unspliced
transcript serves as a template for translation of Gag and Pol
proteins. During particle formation, the unspliced genomic
RNA is also packaged in preference to spliced viral mRNAs
and a more than 1,000-fold excess of cytoplasmic cellular
RNAs. Packaging signals have been identiﬁed in the 59UTR of
lentiviruses (reviewed in [1]). To exclude encapsidation of
spliced viral transcripts, packaging signals of retroviruses are
generally located or extent 39 to the major splice donor. For
members of the c-retrovirus family, a single discrete pack-
aging motif could be identiﬁed that was necessary and
sufﬁcient for RNA encapsidation [2]. For lentiviruses, how-
ever, the situation seems to be more complex, with several
RNA motifs in the 59UTR contributing to packaging
efﬁciency. The major packaging signal of HIV-1 seems to be
a stem loop region designated SL3, the deletion of which
reduces packaging efﬁciency approximately 20-fold [3,4].
However, transfer of the core packaging sequences from the
59UTR to heterologous RNAs did not allow efﬁcient pack-
aging of the heterologous RNA [5], suggesting that additional
factors are important. In HIV-2 and simian immunodeﬁ-
ciency virus (SIV), the major packaging signals are located
upstream of the major splice donor [6–8]. It is unclear how
selective encapsidation of the genomic RNA of HIV-2 and
SIV over spliced viral transcripts is accomplished. As a
potential mechanism, a direct interaction between nascent
Gag and its RNA template has been proposed [6]. Efﬁcient
packaging and transfer of HIV-2- and SIV-based vectors by
HIV-2 particles expressed in trans demonstrates that cotrans-
lational packaging is not an absolute requirement. Alter-
natively, long-distance interactions as observed for the HIV-1
59UTR [9] might lead to different conformations of unspliced
and spliced HIV-2 and SIV transcripts favouring preferential
encapsidation of the unspliced transcript.
One of the small regulatory proteins expressed from a
multiply spliced transcript is the lentiviral Rev protein. Rev
binds to the Rev responsive element (RRE), an RNA motif
present on the unspliced transcript and the env mRNA
(reviewed in [10]). By binding to the RRE, Rev shuttles the
unspliced genomic RNA and the singly spliced env-mRNA via
the CRM-1 export pathway from the nucleus to the
cytoplasm. The unspliced genomic RNA then either serves
as a template for translation of the gag-pol open reading
frames or is packaged into the viral particle. We recently
observed that omitting Rev or deleting the RRE during
production of an HIV-1 vector had only a minor effect on
cytoplasmic vector RNA levels, but reduced vector titers
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found between cytoplasmic RNA levels of HIV vectors
containing a constitutive transport element (CTE) and vector
titers [12]. Both studies indicate that cytoplasmic localization
of genomic vector RNA is not sufﬁcient for vector infectivity,
and suggest that the function of the Rev/RRE system extends
beyond transport of viral RNA from the nucleus to the
cytoplasm. The molecular mechanism responsible for re-
duced titers of RRE-deﬁcient vectors in the presence of
substantial cytoplasmic vector RNA levels has not been
deﬁned. Since a Rev-independent, codon-optimized expres-
sion plasmid for HIV-1 gag-pol was used, the effect of Rev on
vector titers could not be attributed to modulation of particle
production. We therefore analyzed the effect of the Rev-RRE
system on RNA encapsidation into HIV-1 and SIV particles.
For both viruses, packaging efﬁciency of genomic vector
RNA, but not cytoplasmic RNA levels, reﬂected the Rev effect
on vector titers.
Results
HIV-1 Rev Enhances RNA Encapsidation
Infectious HIV-1-based vector particles were produced by
cotransfection of a codon-optimized HIV-1 gag-pol expression
plasmid, a VSV-G expression plasmid, a tat expression
plasmid, and the prototypic HIV-1 vector construct V
H
(Figure 1A) into 293T cells in the presence or absence of a rev
expression plasmid [11]. Vector titers in the absence of Rev
were only 3% of those obtained with Rev (Figure 2A). To
study the role of Rev on packaging efﬁciency, we determined
genomic vector RNA levels in the cytoplasm of transfected
cells and in viral particles pelleted from the supernatant of
transfected cells through a 30% sucrose cushion. Mean
cytoplasmic V
H vector RNA copy numbers per microgram





8 in the presence and absence of Rev, respectively,
matching well with results obtained in Northern blot analyses
(unpublished data). To exclude the possibility that Rev-
independent cytoplasmic localization of vector RNA is simply
due to contamination of the cytoplasmic RNA fraction with
large amounts of nuclear RNA, pre–glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) RNA levels in cytoplasmic
and nuclear RNA preparations were determined by quanti-
tative real-time PCR. As expected for a nuclear RNA, 16-fold
higher concentrations of preGAPDH RNA were observed in
the nuclear fraction than in the cytoplasm (Figure 2C). In
addition, Western blot analysis revealed the presence of
lamin B in the nuclear fraction, but not in the cytoplasmic
fraction, conﬁrming the ﬁdelity of the cell fractionation
procedure (Figure 2D).
Mean V
H vector RNA copy numbers in particles were 5.43
10
8 6 2.03 10
8 per milliliter supernatant of transfected cells
with Rev, and 6.1310
6 6 4.6310
6 per milliliter without Rev.
To normalize encapsidation for cytoplasmic RNA levels, the
ratio of particle-associated RNA copies per milliliter super-
natant and cytoplasmic RNA copies per microgram extracted
RNA was taken as packaging efﬁciency. The ratio obtained
for V
H in the presence of Rev was set as 100%, and the values
of all other samples are given relative to this (Figure 2A).
Omitting Rev reduced the packaging efﬁciency to 3%, while
cytoplasmic RNA levels were only reduced to 44% of those
Figure 1. Map of HIV-1 and SIV Vector Constructs
Opposing arrows mark primer binding sites for the quantitative real-time
PCR. Predicted secondary structures for wild-type (wt RRE) and mutated
RRE are shown, with the grey stem loop representing the MS2-derived
RNA motif. (A) HIV-1 vector constructs, (B) SIV vector constructs.
Blas-EGFP, EGFP cDNA fused in frame to the Blasticidin resistance gene;
CMV, human cytomegalovirus immediate early promoter; EGFP, gene for
the enhanced green fluorescent protein; MLV, murine leukemia virus
promoter; R, direct repeat sequence; SA, splice acceptor; SD, splice
donor; U3, 39 unique sequence; U5, 59 unique sequence.
doi:10.1371/journal.ppat.0030054.g001
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Author Summary
The AIDS pandemic is still an important public health problem,
particularly in developing countries. A comprehensive understand-
ing of the HIV replication cycle might allow development of new
therapeutics. Despite 20 years of extensive research, the intracellular
fate of the different RNAs produced during virus replication is not
fully understood. It is known that the viral regulatory protein Rev
binds to large viral RNAs and shuttles them from the nucleus to the
cytoplasm by a cellular export pathway. We now provide evidence
for a more far-reaching role of Rev. We observed that Rev enhances
packaging of viral RNA into viral particles to a much larger extent
than its effect on viral RNA levels in the cytoplasm. Thus, an early
nuclear event (binding of Rev to the viral RNA) seems to be
intimately linked to RNA encapsidation occurring at a late step of
the viral replication cycle. Since Rev is not part of the viral particles,
Rev seems to act indirectly, possibly by targeting the viral RNA to a
cytoplasmic compartment favourable for RNA encapsidation. Thus,
further studies on the function of Rev might also advance our
understanding of cytoplasmic RNA trafficking and subcytoplasmic
compartmentalization.obtained in the presence of Rev. Thus, Rev enhances
packaging efﬁciency and titer of the HIV-1 vector to a
similar degree.
Rev Enhances RNA Encapsidation into SIV Particles
Analogous experiments were also performed with an SIV
vector packaging system [13] to determine whether the
enhancing effect of Rev on vector RNA packaging is
conserved among primate lentiviruses. Since HIV-1 Rev and
Tat can functionally replace the SIV homologues, SIV vector
particles were prepared by cotransfection of expression
plasmids for codon-optimized gag-pol of SIVmac239, VSV-G,
and HIV-1 tat with a prototypic SIV vector construct (V
S in
Figure 1B) in the presence and absence of the HIV-1 rev
expression plasmid. The same enhancing effect of HIV-1 Rev
on SIV vector titer and vector RNA packaging efﬁciency
(Figure 2B) was observed, while cytoplasmic RNA levels of the
SIV vector were only reduced 2-fold in the absence of Rev. To
analyse whether SIV Rev also enhances RNA encapsidation,
an SIV rev expression plasmid was cotransfected with
expression plasmids for SIV gag-pol, VSV-G, and HIV-1 tat.
Similar to Rev of HIV-1, SIV Rev also enhanced SIV vector
RNA packaging efﬁciency and titer of the SIV vector (Figure
2B).
Rev-Independent Formation of Viral Particles
The enhanced packaging efﬁciency we observed in the
presence of Rev could be due to stimulation of particle
production and release. It has been previously observed that
Rev enhances Gag protein levels in a RRE-dependent manner
to a larger extent than its cytoplasmic mRNA levels [14].
Although this seemed unlikely under our experimental
conditions, since codon-optimized gag-pol expression plas-
mids lacking RRE and 59UTRs were used, we cotransfected
the gag-pol expression plasmids of HIV-1 and SIV in the
presence and absence of the HIV-1 rev expression plasmid.
Particles released in the supernatant were pelleted, and a
Western blot analysis with an anti-HIV-1 p24 capsid (CA)
antibody also cross-reacting with SIV CA was performed. Rev
did not affect the amounts of particles produced by the
codon-optimized expression plasmids, and no obvious differ-
ences in the processing of Gag could be observed (Figure 3A).
In contrast, expression of wild-type gag-pol from an expres-
sion plasmid also containing the HIV-1 RRE (UTRgp-RRE,
Figure 1A) could only be detected in the presence of Rev
(Figure 3B). The large difference at the protein level in
UTRgp-RRE-transfected cultures was not reﬂected in cyto-
plasmic gag-pol RNA levels, which were reduced approx-
imately 5-fold in the absence of Rev (unpublished data).
Relationship of Cytoplasmic RNA Levels and Packaging
Efficiency
The slightly reduced cytoplasmic RNA levels observed in
the absence of Rev could lead to large differences in RNA
packaging due to a non-linear relationship. Therefore,
increasing amounts of the V
H vector plasmid were cotrans-
Figure 2. Effect of Rev on Encapsidation of HIV-1 and SIV Vector RNA
(A) The HIV-1 vector plasmid V
H was cotransfected with expression plasmids for HIV-1 gag-pol, VSV-G, and HIV-1 tat in the presence (þRev) or absence
( Rev) of an HIV-1 rev expression plasmid. Cytoplasmic RNA levels, packaging efficiency, and vector titers are presented relative to the values obtained
in the same transfection experiment with VH in the presence of Rev. The mean value and standard deviation of three to eight independent transfection
experiments are shown.
(B) The SIV vector plasmid V
S was cotransfected with expression plasmids for SIV gag-pol, VSV-G, and HIV-1 tat in the absence ( Rev) or presence of an
SIV (þSIV-Rev) or HIV-1 rev (þRev) expression plasmid. The mean value and standard deviation of four independent transfection experiments are shown.
Numbers above the bars indicate fold induction by Rev.
(C) Using a real-time PCR for preGAPDH RNA, threshold cycle numbers (Ct) were determined for four nuclear (N) and cytoplasmic (C) RNA preparations
in three independent experiments. Relative amounts of preGAPDH RNA levels were calculated as arbitrary units (AU) per microgram extracted RNA by
including 10-fold serial dilutions of standard nuclear RNA preparations. Ct values of a typical experiment are shown in the left panel, and the table
summarizes the results.
(D) Western blot analysis of total cell lysate (T), and cytoplasmic (C) and nuclear (N) fractions for Lamin B.
doi:10.1371/journal.ppat.0030054.g002
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Rev-Mediated Enhancement of RNA Encapsidationfected with constant amounts of packaging plasmids in the
absence of Rev and compared with transfections containing a
small amount of V
H in the presence of Rev. Cytoplasmic RNA
levels obtained with large amounts of V
H in the absence of
Rev were up to 10-fold higher than the levels obtained with a
low amount of V
H in the presence of Rev (Figure 3C). Despite
much lower cytoplasmic RNA levels, particle-associated
vector RNA copies per milliliter supernatant of cells trans-
fected with V
H in the presence of Rev exceeded those
obtained in the absence of Rev. Thus, a non-linear relation-
ship between cytoplasmic RNA levels and packaging efﬁ-
ciency can not explain the differences in packaging efﬁciency
observed.
Instead of measuring packaging efﬁciency as the ratio of
cytoplasmic RNA to particle-associated RNA, the packaging
efﬁciency is frequently determined as amount of vector RNA
per amount of CA. Therefore, pelletable p24 CA levels were
also determined in the supernatant of the transfected cells.
Neither Rev nor the amount of transfected vector plasmid
inﬂuenced p24 CA levels notably. However, the amount of
particle-associated RNA per microgram p24CA was strongly
reduced in the absence of Rev, conﬁrming the inﬂuence of
Rev on RNA packaging (Figure 3C).
Effect of Rev on RNA Encapsidation in Infected Cells
The minor effect of Rev on cytoplasmic vector RNA levels
could be due to overexpression of the vector RNA by
transient transfection. To study the role of Rev on RNA
encapsidation under more natural expression levels, 293T
cells were infected with HIV-1 vector particles transferring
the V
H vector, and a stable cell line, designated 293-V
H, was
established. The V
H vector could be rescued from these cells
at a titer of 5.8 3 10
4 GFU/ml by transient cotransfection of
expression plasmids for HIV-1 gag-pol, VSV-G, tat, and rev.
Mean cytoplasmic vector RNA copy numbers per microgram
extracted RNA were 1 3 10
7 6 4.3 3 10
6,a n dt h u s
approximately 100-fold lower than after transient trans-
fection of the vector construct. Even at these reduced
expression levels, transfection of the rev expression plasmid
only led to a 2-fold increase in cytoplasmic RNA levels (Figure
4A). In contrast, Rev enhanced packaging efﬁciency and the
vector titer 69- and 21-fold, respectively. Similar results were
obtained in cells stably infected with an SIV vector (Figure
4B).
Analysis of RRE Deletion Mutants
To determine whether the newly discovered function of
Rev was dependent on interaction with the RRE, stem loop II
of the RRE, which is essential for Rev binding, was replaced by
a heterologous stem loop from the bacteriophage MS2 in the
context of the V
H vector, resulting in V
H-MS2 (Fig 1A).
Packaging efﬁciency and vector titers of V
H-MS2 in the
presence of Rev were reduced to 9% and 18% of the values
obtained with V
H, respectively (Figure 5A). Despite deletion
of stem loop II of the RRE, Rev enhanced the packaging
efﬁciency and titer of the HIV-1 V
H-MS2 vector by 2.5- and
3.2-fold, respectively (Figure 5A). This minor effect of Rev
could either be due to residual binding of Rev to the
remaining RRE, or to a second Rev-binding site recently
identiﬁed in the 59UTR of HIV-1 [15,16]. Using an SIV vector
containing a deletion of stem loop II of the SIV RRE (V
SDSL
in Figure 1B), HIV-1 and SIV Rev did not enhance packaging
efﬁciency and vector titer either (Figure 5B).
Tethering of Rev to the Vector RNA via a Heterologous
RNA Element
Stem loop II of the RRE of the V
H-MS2 vector had been
replaced by an MS2 stem loop, which is the binding site for
the coat protein of the MS2 bacteriophage. Fusion of the Rev
protein to the MS2 coat protein allowed tethering of Rev to
the MS2 stem loop–containing RNAs independent of the RRE
[17,18]. Cotransfection of an expression plasmid for a fusion
protein of Rev and the MS2 coat protein (Rev-MSC) with V
H-
MS2 enhanced packaging efﬁciency and titer of the V
H-MS2
vector 11-fold (Figure 5A). Thus, Rev-mediated enhancement
of encapsidation efﬁciency largely depends on binding of Rev
to the RRE.
Discussion
The main function attributed to the Rev proteins of
immunodeﬁciency viruses is the shuttling of viral RNAs
containing the RRE from the nucleus to the cytoplasm,
Figure 3. Effect of Rev on Gag-Pol Particle Formation
Viral particles were pelleted from the supernatant of cells transfected in
the presence (þ) or absence (-) of an HIV-1 rev expression plasmid with
codon-optimized gag-pol expression plasmids of SIV (Sgp
syn) and HIV-1
(Hgp
syn) (A) or a wild-type HIV-1 gag-pol expression plasmid (UTRgp-RRE)
(B). Western blot analyses were performed with pelleted particles and a
CA-specific monoclonal antibody (upper panel). To control for trans-
fection efficiency, a GFP expression plasmid had been included during
transfection, and lysates of transfected cells were analyzed using an anti-
GFP antibody (lower panel).
(C) Cytoplasmic and particle-associated vector RNA copy numbers were
determined in cell cultures transfected with different amounts of the V
H
vector plasmid in the presence or absence of Rev expression plasmid. In
addition, pelletable p24CA levels were determined and used to calculate
the packaging efficiency as particle-associated vector RNA copies per
nanogram p24CA.
doi:10.1371/journal.ppat.0030054.g003
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magnitude with which Rev enhanced export of RRE-contain-
ing RNAs varied greatly with experimental conditions reach-
ing from virtually no effect of Rev on cytoplasmic RNA levels
[19] over approximately 10-fold effects [14,20,21], to an
absolute requirement for Rev [22]. A suboptimal level of
splicing is considered to be crucial to reveal the full nuclear
export function of Rev [10]. If splicing is too efﬁcient, the
RRE-containing intron is removed, and potential target
mRNAs of Rev can not accumulate in the nucleus. Inefﬁcient
splicing due to a lack of recognition by splicing factors and
insufﬁcient retention in the nucleus might lead to constitu-
tive export independent of Rev. In addition, the presence of
cis-acting repressive sequences and/or instability sequences in
the viral genome [23–26] most likely also inﬂuences nuclear
retention and thus the degree of Rev responsiveness.
However, even if comparable proviral constructs with
mutations in Rev or RRE were used, the Rev effect on
cytoplasmic RNA levels varied. Transient transfection experi-
ments mostly revealed an approximately 5- to 10-fold
enhancement of cytoplasmic expression levels of Rev-
dependent viral RNAs [14,20,21]. In contrast, in a lymphoid
cell line stably infected with a Rev-negative HIV-1, Rev-
dependent RNAs could not be detected in the cytoplasm,
demonstrating an absolute requirement for Rev under these
experimental conditions [22]. While the transient trans-
fection experiments could be questioned due to overexpres-
sion, a selection bias can not be formally excluded in the
stably infected lymphoid cell lines. Consistent with an
enhanced polysomal association of RRE-containing RNAs
[20], Rev was also found to stimulate protein expression levels
to a greater extent than the cytoplasmic mRNA levels
encoding this protein [14].
We then observed another function of Rev, the enhance-
ment of RNA encapsidation. Since Rev enhances cytoplasmic
levels of viral genomic RNA and gag-pol expression, it is
difﬁcult to analyse the effect of Rev on steps of the viral
replication cycle that depend on cytoplasmic RNA and Gag-
Pol protein levels, particularly in virus-infected cells or in
cells transfected with proviral expression plasmids. The use of
lentiviral vector systems with codon-optimized gag-pol ex-
pression plasmids allowed us to establish experimental
conditions in which gag-pol expression is completely inde-
pendent of the Rev/RRE system [13]. In addition, removal of
large parts of the viral genome, including cis-acting repressive
sequences and/or instability sequences [23–26] from the
vector construct, led to a vector RNA, the cytoplasmic
expression of which was largely independent of the Rev/
RRE system. Under these conditions, the inﬂuence of Rev on
RNA export and expression could be avoided, and the
enhancing effect of Rev on RNA encapsidation became
clearly evident.
Mechanistically, enhancement of RNA encapsidation by
Rev was dependent on Rev binding the vector RNA to be
packaged. A functional RRE was not required, as tethering of
Rev to the vector RNA via a heterologous stem loop also
enhanced packaging. Since Rev is not part of the viral
particle, the question of how Rev enhances RNA encapsida-
tion arises. One attractive hypothesis is that binding of Rev to
the RRE in the nucleus shuttles the viral genomic RNA via the
CRM-1 export pathway to a subcytoplasmic compartment,
facilitating subsequent sequence-speciﬁc interactions of the
nucleocapsid of Gag with the packaging signals in the 59UTR
of the genomic RNA. Colocalization and ﬂuorescence
resonance energy transfer studies suggest a perinuclear
localization for this meeting point [27]. A coupling of nuclear
export and RNA encapsidation would also explain why the
major packaging signals of HIV-1 are not sufﬁcient for
efﬁcient packaging [5,28]. Although a 1.1-kb env gene
fragment containing the RRE enhanced packaging in initial
experiments with a vector containing an extended gag
sequence [28], deletion of the RRE from the env fragment in
a subsequent study with vectors containing only the ﬁrst 43
nucleotides of gag reduced encapsidation levels just 2-fold
[29]. Insertion of a similar env fragment into a heterologous
RNA containing a fragment spanning most of HIV-1 59UTR
and a CTE from Mason-Pﬁzer monkey virus at the 39 end did
not lead to detectable packaging of the transcript [5]. In both
of the latter publications, the RNA to be packaged might have
been efﬁciently transported into the cytoplasm via the TAP-
Figure 4. Effect of Rev on RNA Packaging in Cells Infected with HIV-1- or SIV-Based Vectors
(A) HIV-1-based vectors. 293T cells stably infected with the V
H vector were transfected with Hgp
syn and expression plasmids for VSV-G and HIV-1 tat in
the presence (þRev) or absence ( Rev) of the HIV-1 rev expression plasmid.
(B) SIV-based vectors. 293T cells stably infected with V
S-Blas were cotransfected with Sgp
syn and VSV-G and tat expression plasmids in the presence or
absence of the rev expression plasmid. Cytoplasmic RNA levels, packaging efficiencies, and vector titers are presented relative to those obtained in the
same transfection experiment in the presence of Rev.
The mean value and standard deviation of three independent transfection experiments are shown. Numbers above the bars indicate fold induction by
Rev.
1, result of single transfection experiment.
doi:10.1371/journal.ppat.0030054.g004
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induced export via the CRM-1 pathway even in the presence
of Rev. Despite wild-type levels of cytoplasmic RNA of RRE-
deﬁcient, CTE-containing vectors, titers were severely im-
paired [12]. This would suggest that export via the CRM-1
pathway is necessary for efﬁcient packaging of the genomic
RNA of lentiviruses. However, substitution of the RRE of
HIV-1 by the CTE in the context of proviral expression
plasmids led to efﬁcient packaging [31]. Under these
experimental conditions, nuclear export of both the gag-pol
encoding RNA and the genomic RNA to be packaged are
dependent on the CTE. Therefore, it seems that the pack-
aging efﬁciency can also be inﬂuenced by the export pathway
of the gag-pol encoding RNA. This is further supported by the
observation that subcellular localization of Gag and HIV-1
virion assembly in murine cells greatly depends on the export
pathway of the encoding mRNA [32]. Export of the gag-pol
encoding RNA and the genomic RNA to be packaged by the
same specialized export pathway might lead to enrichment of
nascent Gag protein and packageable RNA in a subcytoplas-
mic compartment facilitating encapsidation. Although an
inﬂuence of the nuclear export pathway of the gag encoding
RNA on packaging efﬁciency and/or vector titers would
reconcile results from the literature, this hypothesis needs to
be addressed directly. At present, alternative hypotheses, in
which Rev tethers the viral genomic RNA to Gag via bridging
cellular proteins prior to dissociation of Rev from the RRE
independent of the nuclear export function, can not be
excluded either.
Whatever the precise mode of action, the magnitude of the
effect of Rev on packaging is comparable to or exceeds the
effect of deletions of parts of the multipartite HIV-1
packaging signal. Deletion of SL3, the dominant packaging
domain in the 59UTR of HIV-1, reduces RNA encapsidation
approximately 20-fold [3,4], while Rev enhanced RNA pack-
aging 23- to 69-fold. Thus, in addition to interaction of the
nucleocapsid of Gag with the packaging signal at the 59 end of
the genome, the Rev/RRE system provides lentiviruses with a
second mechanism contributing to preferential encapsida-
tion of genomic RNA.
Materials and Methods
Plasmids. The HIV-1 vector constructs HIV-CLCG [33] and HIV-
CLCG-MS [11] were modiﬁed by insertion of nucleotide sequences
1115 to 1329 of SIVmac239 (numbering according to GenBank entry
M33262) in antisense orientation into the blunt-ended EcoN1 site of




reference [34]) contains nucleotide sequences 1–2030, 8015–9499,
9689–9731, and 10057–10535 of the proviral SIVmac239 clone. Stem
loop II (nucleotides 8482–8548) of the SIV-RRE was deleted by
overlap extension PCR, resulting in V
SDSL. The green ﬂuorescent
protein (GFP) Blasticidin fusion gene expressing vector V
SBlas was
constructed by deleting nucleotides 8899–9375 and all remaining
nucleotides between 2031 and 8014 from VGBlasDBH [35].
The expression plasmids encoding VSV-G (pHIT-G), HIV-1 tat
(pcTat), HIV-1 rev (pcRev), a fusion protein of HIV-1 Rev and capsid
of bacteriophage MS2 (Rev-MSC), and codon-optimized gag-pol of
HIV-1 and SIV, have been described previously [13,17,36,37]. An 840-
bp fragment encompassing the RRE of HIV-1 was inserted into the
Xho-I site of pcUTRgp [13] to generate UTRgp-RRE.
Production and characterization of vector particles. Vector-
containing particles were produced by transfection of 293T cells
using the calcium phosphate coprecipitation method as described
[38]. Two days after transfection, the supernatant of the transfected
cells was passed through a 0.45-lm ﬁlter and stored at 80 8C or used
directly for titration on 293 cells [39]. Viral particles were also
pelleted through a 30% sucrose cushion by ultracentrifugation and
analyzed by Western blot with the HIV-1 p24-speciﬁc antibody 183-
H12-5C (US National Institutes of Health [NIH] AIDS Research and
Reference Reagent Program, http://www.aidsreagent.org) directed
against HIV-1 and SIV capsid. The amount of pelleted p24CA was
determined using the INNOTEST HIV Antigen mAb Kit (Innoge-
netics, http://www.innogenetics.com). To control for transfection
efﬁciency, GFP expression was determined in lysates of transfected
cells using an anti-GFP antibody (Santa Cruz Biotechnology, http://
www.scbt.com). For establishment of stable cell lines 293-VH or 293-
V
SBlas, vector-containing particles were produced as described
above. 293T cells were transduced with V
H vector particles on three
consecutive days. Cells were then sorted for GFP expression by ﬂow
cytometry, resulting in a population of 78% GFP-positive cells. For
293-V
SBlas cells, 293T-cells were transduced once and selected for
Blasticidin resistance essentially as described [35].
Packaging assay. To prepare cytoplasmic RNA, trypsinized cells
were washed with PBS, and the plasma membrane was permeabilized
in buffer RLN (50 mM Tris-Cl, 140 mM NaCl, 1.5 mM MgCl2, 0.5%
Nonidet P-40, 1,000 U/ml RNase inhibitor, 1 mM DTT) for 5 min on
Figure 5. Relevance of the Rev–RRE Interaction
(A) An HIV-1 vector plasmid in which stem loop II of the RRE was replaced by the MS2 stem loop was cotransfected with expression plasmids for HIV-1
gag-pol, VSV-G, and tat in the absence ( Rev) or presence of a rev (þRev) expression plasmid, or in the presence of an expression plasmid encoding a
fusion protein of Rev and the MS2 coat protein (þRev-MSC). (B) An SIV vector with a deletion (V
SDSL in Figure 1B) of stem loop II of the RRE was
cotransfected with expression plasmids for SIV gag-pol, VSV-G, and tat in the absence ( Rev) or presence of an HIV-1 (þRev) or SIV rev expression
plasmid. Cytoplasmic RNA levels, packaging efficiency, and vector titers were determined as described, and all values are expressed relative to the
values obtained in the same transfection experiment for the parental V
H (A) and V
S (B) vectors in the presence of Rev, which were set as 100%.
Mean value and standard deviation of at least three independent transfection experiments are shown. Numbers above the short vertical lines indicate
fold induction by Rev.
doi:10.1371/journal.ppat.0030054.g005
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4 8C. The supernatant was harvested as cytoplasmic fraction from
which the RNA was isolated with the RNeasy Mini Kit (Qiagen, http://
www.qiagen.com). Viral particles pelleted as described above were
resuspended in 140 ll of PBS, and RNA was extracted using the
QIAmp Viral RNA Mini Kit (Qiagen).
Cytoplasmic and particle-associated RNA levels of V
H,V
S, and
their derivatives were determined by quantitative real-time PCR as
described previously [39]. This PCR detects a 215-bp fragment
spanning the major splice donor of SIVmac239. To allow detection of
genomic HIV vector RNAs with the same PCR, the SIV PCR fragment
had been introduced into the HIV-1 vector constructs in antisense
orientation downstream of the truncated gag gene. Omitting the
reverse transcriptase from the RT-PCR was used to conﬁrm
elimination of transfected plasmid DNA by DNAse treatment of
extracted RNA samples.
To validate the cellular fractionation procedure, cytoplasmic RNA
was extracted as described above. Nuclear RNA was also extracted
from the pelleted nuclei after one washing step in PBS. Then, 500 ng
of cytoplasmic and nuclear RNA were analyzed by quantitative real-
time PCR with the primers preGAP-DHE6s and preGAP-DHE6a
amplifying intronic sequences of the preGAPDH RNA [39]. Serial
dilutions of nuclear RNA served as standards and allowed us to
determine the ratio of cytoplasmic to nuclear preGAPDH RNA levels.
In addition, the protein content of the nuclear pellet (prepared as
described above and resuspended in lysis buffer [50 mM Tris-HCl (pH
7.4); 150 mM NaCl; 40 mM NaF; 5 mM EDTA; 5 mM EGTA; 1% (v/v)
Nonidet P-40; 0.1% (w/v) Natriumdesoxycholat; 0.1% (w/v) SDS]) and
the cytoplasmic fraction was determined using the Bio-Rad protein
assay (Bio-Rad, http://www.bio-rad.com). Next, 40 lg protein of each
fraction were analyzed by Western blot using the anti-Lamin B
antibody C-20 (Santa Cruz Biotechnology). A total cell lysate was also
included.
A heterologous RNA transiently expressed at comparable levels in
the cytoplasm was packaged approximately 500-fold less efﬁcient as
the vector RNAs, conﬁrming the speciﬁcity of the packaging assay
[39]. Cytoplasmic RNA levels of UTRgp-RRE were determined by an
HIV-1 gag-speciﬁc RT-PCR using primers SK145 and SKCC1B from
the Amplicor HIV-1 Monitor test [40].
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